NeoGenomics Inc (NEO)
13.94
-1.28
(-8.41%)
USD |
NASDAQ |
Apr 30, 16:00
13.92
-0.02
(-0.14%)
After-Hours: 04:49
NeoGenomics Cash from Financing (Quarterly): 1.27M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.27M |
| September 30, 2023 | 1.841M |
| June 30, 2023 | 0.064M |
| March 31, 2023 | 1.379M |
| December 31, 2022 | 1.802M |
| September 30, 2022 | 2.959M |
| June 30, 2022 | 1.011M |
| March 31, 2022 | 6.057M |
| December 31, 2021 | 2.46M |
| September 30, 2021 | -6.72M |
| June 30, 2021 | 204.61M |
| March 31, 2021 | 524.94M |
| December 31, 2020 | 8.265M |
| September 30, 2020 | 4.115M |
| June 30, 2020 | 222.60M |
| March 31, 2020 | 0.617M |
| December 31, 2019 | -3.158M |
| September 30, 2019 | 0.137M |
| June 30, 2019 | 162.00M |
| March 31, 2019 | 0.483M |
| December 31, 2018 | 4.547M |
| September 30, 2018 | 102.78M |
| June 30, 2018 | -8.124M |
| March 31, 2018 | -7.249M |
| December 31, 2017 | -1.67M |
| Date | Value |
|---|---|
| September 30, 2017 | -3.854M |
| June 30, 2017 | -1.775M |
| March 31, 2017 | 3.204M |
| December 31, 2016 | -15.00M |
| September 30, 2016 | -0.571M |
| June 30, 2016 | -0.082M |
| March 31, 2016 | -10.22M |
| December 31, 2015 | 60.81M |
| September 30, 2015 | -0.859M |
| June 30, 2015 | -0.642M |
| March 31, 2015 | -0.812M |
| December 31, 2014 | -0.609M |
| September 30, 2014 | 32.76M |
| June 30, 2014 | -3.552M |
| March 31, 2014 | 0.409M |
| December 31, 2013 | 0.935M |
| September 30, 2013 | -1.028M |
| June 30, 2013 | -1.486M |
| March 31, 2013 | 4.329M |
| December 31, 2012 | 0.181M |
| September 30, 2012 | 1.231M |
| June 30, 2012 | -0.535M |
| March 31, 2012 | 2.507M |
| December 31, 2011 | -0.701M |
| September 30, 2011 | 0.346M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-6.72M
Minimum
Sep 2021
524.94M
Maximum
Mar 2021
59.80M
Average
1.841M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| Teladoc Health Inc | 1.751M |
| Abbott Laboratories | -2.052B |
| Halozyme Therapeutics Inc | -249.92M |
| Verastem Inc | -0.446M |
| Ocugen Inc | 0.016M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 17.78M |
| Cash from Investing (Quarterly) | 17.20M |
| Free Cash Flow | -30.70M |
| Free Cash Flow Per Share (Quarterly) | 0.0852 |
| Free Cash Flow to Equity (Quarterly) | 10.00M |
| Free Cash Flow to Firm (Quarterly) | 10.73M |
| Free Cash Flow Yield | -1.76% |